TWi Biotechnology, Inc.
- Biotech or pharma, therapeutic R&D
TWiB is specializing in the development of innovative new drugs for innate immunity diseases, dermatological diseases, rare disease and depression. TWiB's pipeline includes rare skin disease such as epidermolysis bullosa and common skin disease like vitiligo and AD and depression such as postpartum depression (PPD) and major depressive disorder (MDD).
- AC-203: a topical formulation of 1% diacerein being developed for EBS. An international, multicenter, randomized, double-blind, vehicle-controlled, phase 2/3 study with open-label extension study, referred to as the EBShield Study, is currently underway.
- AC-1101: a propriety topical gel formulation of Tofacitinib Citrate, a JAK inhibitor, for inflammatory skin diseases. A Phase 1b clinical study on Granuloma Annulare in the US was completed in 2024.
- NORA520, is an innovative oral prodrug of Brexanolone designed for the treatment of PPD and MDD, each targeting a rapidly growing patient population with unmet medical needs.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}